Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia.

Junk SV, Klein N, Schreek S, Zimmermann M, Möricke A, Bleckmann K, Alten J, Dagdan E, Cario G, Kratz CP, Schrappe M, Stanulla M.

Haematologica. 2019 Jul 9. pii: haematol.2018.205849. doi: 10.3324/haematol.2018.205849. [Epub ahead of print]

2.

Corrigendum: S100-alarmin-induced innate immune programming protects newborn infants from sepsis.

Ulas T, Pirr S, Fehlhaber B, Bickes MS, Loof TG, Vogl T, Mellinger L, Heinemann AS, Burgmann J, Schöning J, Schreek S, Pfeifer S, Reuner F, Völlger L, Stanulla M, von Köckritz-Blickwede M, Glander S, Barczyk-Kahlert K, von Kaisenberg CS, Friesenhagen J, Fischer-Riepe L, Zenker S, Schultze JL, Roth J, Viemann D.

Nat Immunol. 2017 Sep 19;18(10):1173. doi: 10.1038/ni1017-1173b. No abstract available.

PMID:
28926540
3.

S100-alarmin-induced innate immune programming protects newborn infants from sepsis.

Ulas T, Pirr S, Fehlhaber B, Bickes MS, Loof TG, Vogl T, Mellinger L, Heinemann AS, Burgmann J, Schöning J, Schreek S, Pfeifer S, Reuner F, Völlger L, Stanulla M, von Köckritz-Blickwede M, Glander S, Barczyk-Kahlert K, von Kaisenberg CS, Friesenhagen J, Fischer-Riepe L, Zenker S, Schultze JL, Roth J, Viemann D.

Nat Immunol. 2017 Jun;18(6):622-632. doi: 10.1038/ni.3745. Epub 2017 May 1. Erratum in: Nat Immunol. 2017 Sep 19;18(10 ):1173.

PMID:
28459433
4.

MicroRNA miR-548d is a superior regulator in pancreatic cancer.

Heyn H, Schreek S, Buurman R, Focken T, Schlegelberger B, Beger C.

Pancreas. 2012 Mar;41(2):218-21. doi: 10.1097/MPA.0b013e318224b701.

PMID:
21946813
5.

MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development.

Heyn H, Engelmann M, Schreek S, Ahrens P, Lehmann U, Kreipe H, Schlegelberger B, Beger C.

Int J Cancer. 2011 Dec 15;129(12):2797-806. doi: 10.1002/ijc.25962. Epub 2011 May 25.

6.

Mutations in neutrophil elastase causing congenital neutropenia lead to cytoplasmic protein accumulation and induction of the unfolded protein response.

Köllner I, Sodeik B, Schreek S, Heyn H, von Neuhoff N, Germeshausen M, Zeidler C, Krüger M, Schlegelberger B, Welte K, Beger C.

Blood. 2006 Jul 15;108(2):493-500. Epub 2006 Mar 21.

7.

PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation.

Yu M, Schreek S, Cerni C, Schamberger C, Lesniewicz K, Poreba E, Vervoorts J, Walsemann G, Grötzinger J, Kremmer E, Mehraein Y, Mertsching J, Kraft R, Austen M, Lüscher-Firzlaff J, Lüscher B.

Oncogene. 2005 Mar 17;24(12):1982-93.

PMID:
15674325
8.

Tumorigenic N-terminal deletions of c-Myb modulate DNA binding, transactivation, and cooperativity with C/EBP.

Oelgeschläger M, Kowenz-Leutz E, Schreek S, Leutz A, Lüscher B.

Oncogene. 2001 Nov 1;20(50):7420-4.

9.

Regulatory domains of the A-Myb transcription factor and its interaction with the CBP/p300 adaptor molecules.

Facchinetti V, Loffarelli L, Schreek S, Oelgeschläger M, Lüscher B, Introna M, Golay J.

Biochem J. 1997 Jun 15;324 ( Pt 3):729-36.

10.

Interaction of the co-activator CBP with Myb proteins: effects on Myb-specific transactivation and on the cooperativity with NF-M.

Oelgeschläger M, Janknecht R, Krieg J, Schreek S, Lüscher B.

EMBO J. 1996 Jun 3;15(11):2771-80.

11.

Regulation of transcription factors c-Myc, Max, and c-Myb by casein kinase II.

Bousset K, Oelgeschläger MH, Henriksson M, Schreek S, Burkhardt H, Litchfield DW, Lüscher-Firzlaff JM, Lüscher B.

Cell Mol Biol Res. 1994;40(5-6):501-11.

PMID:
7735324

Supplemental Content

Loading ...
Support Center